TVGH-NYCU Research Team Unveils Breakthrough in Lung Adenocarcinoma: New Mechanism Identified to Overcome Drug Resistance
A research team from National Yang Ming Chiao Tung University (NYCU) and Taipei Veterans General Hospital (TVGH) has made a groundbreaking discovery in the fight against lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC). The team identified a key mechanism behind tumor growth and metastasis, which could potentially lead to strategies that overcome drug resistance—an issue that has plagued the treatment of lung cancer despite advancements in medical technology.
Unveiling the Tumor’s Immune Evasion Tactics
Lung cancer remains the leading cause of cancer-related deaths in Taiwan, with NSCLC accounting for approximately 85% of cases. Among them, adenocarcinoma is the most prevalent subtype. One of the significant challenges in treating lung adenocarcinoma is its tendency to metastasize and develop resistance to therapies. Researchers discovered that a transcription factor known as NKX2-1, crucial for lung tissue differentiation, plays a pivotal role in the tumor microenvironment.
The team found that reduced expression of NKX2-1 is closely associated with tumor progression and poor prognosis. This decrease triggers tumor cells to manipulate the immune system, particularly neutrophils—white blood cells that typically serve as the body’s first line of defense. Instead of attacking the tumor, these cells are recruited to support its growth and spread.
The Switch: Why Do White Blood Cells Aid Tumor Growth?
While the scientific community has long known that NKX2-1 is a key regulator in lung tissue differentiation, its downstream mechanisms have remained elusive—until now. The research, led by Professor Shih-Hwa Chiou from NYCU’s Institute of Pharmacology, found that when NKX2-1 expression decreases, cancer cells secrete CXCL chemokines. These chemokines interact with CXCR2 receptors on neutrophils, persuading them to enter the tumor microenvironment and inadvertently assist in tumor growth and metastasis.
“Neutrophils are the most abundant white blood cells and form the first line of innate immune defense,” explained Professor Chiou. “However, more and more studies confirm that in the tumor microenvironment, these immune cells can be subverted by cancer cells, supporting tumor growth instead of fighting it and contributing to drug resistance.”
Validating the Mechanism in Animal Models
The research team validated this mechanism in animal models, successfully reducing tumor growth by targeting the CXCR2 receptor with an antagonist. This suggests that CXCR2-targeted therapies may hold promise as a future treatment strategy for lung adenocarcinoma patients, offering a way to overcome drug resistance and improve outcomes.
“This study further highlights the potential of NKX2-1 as a clinical biomarker for lung adenocarcinoma,” said Professor Chiou. “Understanding the role of NKX2-1 in shaping the immune microenvironment provides valuable insights into the complex interactions between cancer cells and the immune system, opening up new avenues for therapeutic interventions.”
A Collaborative Effort with Global Impact
The research was a collaborative effort between Professor Chiou and Dr. Mong-Lien Wang, Associate Research Fellow at TVGH’s Department of Medical Research. The project was executed by Anita S. La’ah, a Nigerian Ph.D. student in the Taiwan International Graduate Program (TIGP) of Academia Sinica. The findings were published in the prestigious journal Advanced Science. La’ah’s groundbreaking contributions earned her a Ph.D. in Molecular Medicine from NYCU College of Life Sciences this July. She now has the opportunity to continue her research in the United States.
These findings mark a significant step forward in the fight against lung cancer, offering hope for more effective treatments and highlighting the potential of immunotherapy in overcoming one of the most challenging aspects of cancer treatment: drug resistance.
